Nvidia-backed Iambic Therapeutics tumbles below IPO price

By Reuters News

** Shares of Iambic Therapeutics IAM.O, drug developer backed by AI giant Nvidia NVDA.O, tumble as much as 41% to $14.10 in their third session of trading on Mon

** IAM opened at $16.15 on Thurs after $150 mln IPO priced at $16, midpoint of the marketed range

** Stock finished up ~26% on Fri at $23.81 after rising to as high as $25

** Biotech IPOs have continued to get done even as market volatility and surging bond yields combine to dampen investor appetite for new listings

** Iambic is advancing a pipeline of drug candidates developed using its AI platform to treat solid tumors. It has partnerships with top pharma companies, including AbbVie ABBV.N and Takeda Pharmaceutical 4502.T

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk